Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Verastem, Inc. (VSTM) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including Forms 8-K, 10-K, 10-Q, and registration statements filed with the U.S. Securities and Exchange Commission. Verastem’s filings document its status as a Nasdaq-listed biopharmaceutical issuer focused on RAS/MAPK pathway-driven cancers, with common stock registered on The Nasdaq Capital Market under the symbol VSTM.
Recent Form 8-K reports highlight several important areas for investors: underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement on Form S-3, preliminary and updated clinical data for the KRAS G12D inhibitor VS-7375, and company communications regarding AVMAPKI FAKZYNJA CO-PACK, an FDA-approved combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. These current reports also reference updated corporate presentations and conference materials that outline Verastem’s pipeline and strategy.
For a biopharmaceutical company like Verastem, periodic reports such as Forms 10-K and 10-Q (when available) typically contain detailed information on research and development spending, commercialization activities for AVMAPKI FAKZYNJA CO-PACK, risk factors related to oncology drug development, and the status of key clinical programs such as RAMP 301, RAMP 205, and VS-7375-101. Capital structure changes, including equity offerings and warrant terms, are also described in registration statements and accompanying exhibits.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain complex sections in plain language, highlight material events, and surface items of interest such as financing transactions, clinical trial disclosures, and changes in capital markets activity. Users can quickly scan new 8-Ks, 10-Qs, and 10-Ks for Verastem, review details of public offerings and warrant structures, and explore how regulatory filings align with the company’s oncology pipeline and commercial strategy.
Verastem Inc received an Amendment No. 2 to Schedule 13G/A from The Vanguard Group reporting that, following an internal realignment, certain Vanguard subsidiaries will report beneficial ownership separately. The filing states amount beneficially owned: 0 and percent of class: 0%. The amendment cites SEC Release No. 34-39538 (January 12, 1998) as the basis for disaggregated reporting and is signed by Vanguard's Head of Global Fund Administration.
Calkins Daniel reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc.’s Chief Financial Officer Daniel Calkins received a grant of 57 shares of common stock on March 20, 2026 at a value of $5.74 per share. This was a compensation-related award, not an open-market purchase. Following the grant, he directly holds 121,327 common shares.
Verastem, Inc. filed a current report to let investors know it has posted an updated corporate presentation on its website. The presentation, dated March 4, 2026 and filed as Exhibit 99.1, is provided under Regulation FD to share the same information with all market participants.
Verastem, Inc. outlines a pivotal year transforming into a commercial-stage oncology company focused on RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S., the first FDA-approved therapy specifically for KRAS‑mutated recurrent low‑grade serous ovarian cancer.
AVMAPKI FAKZYNJA CO-PACK received accelerated approval in May 2025, was commercially available within a week, and generated $30.9 million in net product revenue over its first seven months. A global Phase 3 confirmatory trial (RAMP 301) fully enrolled ahead of schedule and is intended to support full approval and a broader LGSOC label.
Beyond LGSOC, Verastem is advancing avutometinib plus defactinib in first-line pancreatic cancer (RAMP 205) and developing VS-7375, a selective oral KRAS G12D ON/OFF inhibitor licensed from GenFleet. VS-7375 is in U.S. Phase 1/2 trials and has FDA Fast Track designations in KRAS G12D-mutated pancreatic cancer.
Verastem, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 3,536,000 shares of common stock, representing 5.30% of the class as of 12/31/2025. The filing states Armistice Capital exercises shared voting and dispositive power over these shares under its Investment Management Agreement; the Master Fund is the direct holder. The filing is a joint Schedule 13G signed on 02/17/2026.
Verastem, Inc. received an amended ownership report from Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen, stating beneficial ownership of 995,026 common shares, or 1.3% of the company’s outstanding stock as of December 31, 2025. These shares are held through an investment fund managed by Point72 Asset Management, with voting and investment power shared among the reporting entities. The filers certify that the position is not held for the purpose of changing or influencing control of Verastem.
RTW Investments and Roderick Wong reported beneficial ownership of 7,836,346 shares of Verastem common stock, representing 9.9% of the class. All voting and dispositive power over these shares is shared, with no sole authority reported by either party.
The ownership figure assumes the exercise of warrants held by the reporting persons to purchase 1,260,040 shares, subject to a 9.99% ownership cap in the warrant terms. The percentage is based on 66,776,006 shares outstanding as of November 3, 2025, plus 10,405,863 shares issued in a later public offering and the warrant shares. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Verastem.
Balyasny Asset Management and affiliates report a 6.18% beneficial stake in Verastem Inc. common stock. The group reports beneficial ownership of 4,767,154 shares, consisting of 3,195,726 shares and 1,571,428 shares issuable upon exercise of warrants that are subject to a 9.99% beneficial ownership blocker.
The percentage is based on 77,154,709 Verastem shares outstanding as of November 17, 2025. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Verastem.
Nantahala Capital Management, LLC and its principals report a significant but sub‑5% stake in Verastem, Inc. They disclose beneficial ownership of 3,795,473 shares of Verastem common stock, representing 4.72% of the outstanding class as of December 31, 2025.
The filing states that Nantahala, Wilmot B. Harkey, and Daniel Mack share voting and dispositive power over these shares and have no sole voting or dispositive authority. They certify that the securities were acquired and are held in the ordinary course of business, not to change or influence control of Verastem.
Verastem, Inc. President and CEO Dan Paterson reported a small sale of company stock tied to tax withholding. On February 4, 2026, he sold 970 shares of common stock at $6.69 per share to satisfy statutory withholding for vested restricted stock units.
After this transaction, Paterson directly held 612,919 shares of Verastem common stock, indicating he retains a substantial equity stake despite the routine tax-related sale.